Contact
searchSearch
HMP Global
Login

Tardive Dyskinesia

Tardive Dyskinesia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Q&A
Improving Tardive Dyskinesia Detection Through Routine Clinical Monitoring
08/03/2026
Brooke Kempf, MSN, PMHNP-BC; Jonathan Meyer, MD
Jonathan Meyer, MD, and Brooke Kempf, PMHNP-BC, offer their thoughts on how to incorporate both observational and structured TD assessment into everyday practice. 
Jonathan Meyer, MD, and Brooke Kempf, PMHNP-BC, offer their thoughts on how to incorporate both observational and structured TD assessment into everyday practice. 
Jonathan Meyer, MD, and Brooke...
08/03/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Treating Beyond AIMS Scores: Tracking Functional Outcomes in Tardive Dyskinesia
05/12/2026
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD,...
05/12/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Quiz
Why should anticholinergics be avoided in TD?
04/17/2026
Maria Mantas
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why anticholinergic agents aren't appropriate treatment options for tardive dyskinesia? Test your knowledge with this quiz!
Do you remember why...
04/17/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Q&A
Recognizing Key Differences Between TD and Drug-Induced Parkinsonism
03/10/2026
Brooke Kempf, MSN, PMHNP-BC; Jonathan Meyer, MD
In this Q&A, Brooke Kempf, PMHNP-BC, Steering Committee, Psych Congress, and Jonathan Meyer, MD, Consultant, Psych Congress, outline the hallmark characteristics of DIP and TD.
In this Q&A, Brooke Kempf, PMHNP-BC, Steering Committee, Psych Congress, and Jonathan Meyer, MD, Consultant, Psych Congress, outline the hallmark characteristics of DIP and TD.
In this Q&A, Brooke Kempf,...
03/10/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD
Q&A
Avoiding Anticholinergics in TD and Deprescribing Approaches
02/06/2026
Brooke Kempf, MSN, PMHNP-BC; Jonathan Meyer, MD
In this discussion, Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD, unpack why anticholinergics are ineffective—and potentially harmful—in patients with tardive dyskinesia (TD). 
In this discussion, Brooke Kempf, PMHNP-BC, and Jonathan Meyer, MD, unpack why anticholinergics are ineffective—and potentially harmful—in patients with tardive dyskinesia (TD). 
In this discussion, Brooke...
02/06/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Desiree Matthews
Videos
Anticipating Medication Interactions in Tardive Dyskinesia
08/01/2025
Desiree Matthews, PHMNP-BC
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC,...
08/01/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use